Mink therapeutics reports Q1 2025 results and highlights

• Clinical data builds with CR with testicular cancer, enrollment in phase-2 stomach study and new data in PD-1-resistant tumors

• Short -term capital transactions to strengthen liquidity

New York, May 15, 2025 (Globe Newswire)-Mink Therapeutics, Inc. (Nasdaq: Inkt), A Clinical Stage Biopharmaceutical Pioneering the Development of AllogeneIic, Off-the-Shelf Invarient Natural Killer, Today Announ ITS Financial Results for the First Quarter of 2025 and Provided A Business Update Highlighting Continued Clinical Progress and Strategic Developments Across ITS Inkt platform. The company will organize a telephone conference and webcast today at 8:30 a.m.

“This quarter marks a turning point in the development of nerz. Our platform shows the power of Inkt cells, immune responses to transform in both cancer and inflammatory diseases,” said Jennifer Buzer, Ph.D., President and Chief Executive Officer from Mink Therapeutics. “With strategic discussions in the late level in technical cell therapies in oncology, immunology and next generation, Mink is positioned in order to unlock the full value of our technology. These partnerships enable us through our clinical advances and the extended access to non -dilutive capital.

Important highlights from Q1 2025

Strategy and business development

• Advanced discussions about various transactions, which are aligned with the core areas of the mink platform incubation, immune-mediated diseases and the next generation, are designed to expand the range of Mink and at the same time maintain the optionality and the shareholder value.

Clinical progress in cancer, immunity and inflammation

Mink continues to expand the clinical and strategic value of its tinkt platform to solid tumors and immune-mediated diseases.

• At AACR IO and ASCO GI, Nink presented new data that showed that Agent-797, in combination with checkpoint inhibitors and chemotherapy, drives fast tumor infiltration, CD8+ T cell activation and immune programming in PD-1-resistant gastrosophageal cancer with limited therapeutic options.
• A phase 2 study (NCT06251973) under the direction of the Memorial Sloan Kettering Cancer Center actively introduces stomach cancer in the second place.
• A publication assessed by experts, which is expected in the first half of 2025, will describe a complete remission in a patient with metastatic testicular cancer, which is dealt with in the Mink phase 1 study with a single infusion of AGENT-797-without lymphodepletion, HLA matching or toxicity. This case increases the differentiated potential of the off-the-shelf platform from Mink in solid tumors that are refractory for standard treatments and immunotherapy.
• In ARDS, Mink's incidental therapy continues to show the survival advantage and inflammatory control, as published Natural communication And presents in the American Thoracic Society. The company pursues a broader access to the patient through clinical studies and compassionate usage programs.
• At the same time, Mink was selected by Niaid for the likely financing to support his allogeneic ink program in GVHD, whereby a formal award is expected until June 2025. This recognition adds a critical source for non -dilutive capital and external validation of the guidance of mink in inflammation and immune modulation.

Together, these programs represent high -quality expansion options in the core vertical of Mink: solid tumors, inflammatory diseases and technical cell therapies of the next generation.

Financial highlights

Mink ended the quarter with a cash balance of 3.2 million US dollars. Cash that was put into operation for the three months on March 31, 2025 was $ 1.3 million compared to USD 2.5 million for the same period of 2024. The net loss in the first quarter of 2025 was $ 2.8 million or $ 0.70 per share compared to USD $ 3.8 million per share for the first quarter of 2024.

Summary consolidated financial information
Concert consolidated balance sheet data
(in thousands)
(unchecked)
	March 31, 2025				December 31, 2024
Cash and cash equivalent	$	3.235			$	4.577
Total assets		4.267				5.721
Other financial information
(in thousands)
(unchecked)
	Three months ended on March 31,
		2025				2024
Cash used in the company	$	1.341			$	2.542
Non-revenue costs		835				650
Concert consolidated statements of the operation data
(In thousands, except that data data)
(unchecked)
	Three months ended on March 31,
		2025				2024
Operating costs:
Research and Development	$	1,262			$	2,550
General and administrative		1.271				1.280
Change of the time value of the related partnership		168
Operating loss		2.701				3.830
Other income, network		66				(17	)))
Net	$	2.767			$	3.813
By joint stock data, fundamental and diluted:
Net	$	(0.70	)))		$	(1.10	)))
Weighted average number of ordinary shares, fundamentally and diluted		3.965				3.464

Telephone conference

Dial-in numbers: 646-307-1963 (New York), 800-715-9871 (USA & Canada)

Conference -ID: 9822477

Webcast

A live webcast and a repetition of the call to the conference are accessible via the website of events & presentation on the company's website at via

About nerz therapy

Mink Therapeutics is a biopharmaceutical company in the clinical stage that includes the discovery, development and commercialization of allogeneous invariant of natural killer cell therapies (Tinn) for the treatment of cancer and other immune-mediated diseases. Mink promotes a pipeline both native and the next generation of technical ink programs with a platform with which the scalable and reproducible production is facilitated for the delivery of the shot. The company has its headquarters in New York, NY. For more information, see @mink_inkt. Information that can be important for investors are routinely published on our website and social media channels.

About Agent-797

Agent-797 is an allogeneic invariant natural killer cell therapy that uses the double power of innate and adaptive immunity. Incts act as “main regulators” and combine the cytotoxic skills of NK cells with T cell-like antigen recognition and memory. This unique biology enables a robust, pathogen-agony immune response, which can be directed against tumors to be treated.

Agent-797 by Nerk Therapeutics in Lexington, MA, is a scalable product that offers accessible, transformative treatment options. In clinical studies, AGENT-797 can strengthen the T cell activation of peripheral memory, improve tumor infiltration and possibly improve results for patients with solid cancer (Cytry et al. AACR IO 2024, oncogenes 2024) and combating inflammation in critically sick patients with serious patients Respiratory patronity (heavy patients) (to fightNatural communication. 2024).

Looking -looking statements

This press release contains future -oriented statements that have been made in accordance with the provisions of the secure securities laws of the safe port, including statements on the therapeutic potential, the expected advantages, plans and schedules for ink cells as well as the cooperation between Mink and Agenus. These future -oriented statements are subject to risks and uncertainties that can lead to the fact that the actual results differ significantly. These future-oriented statements are subject to risks and uncertainties, including the factors that have been submitted in the section risk factors of the latest form 10-K, form 10-Q and the S-1 registration declaration of the SEC. Mink is waiting for investors that the future -oriented statements contained in this publication have no considerable dependence on the future -oriented statements. These statements only speak at the time of this press release and Nerink and Agenus without obligation to update or revise the statements, except to the statutory extent. All future -oriented statements are expressly qualified by this warning explanation.

Investor contact

917-362-1370

investor@minctapeutics.com

Media contact

781-674-4428

Communications@minctapeutics.com